Moderna has been identified as one of the best growth stocks for long-term investment. The company's combination
Covid and flu mRNA shot have outperformed other vaccines in a large trial. A considerable stock position ($78.76 million) has been taken by Deutsche Bank AG in Moderna. HHS is planning to pay $176 million to Moderna for their mRNA Flu Vaccine. However, HHS is also reported to stop recommending Covid shots for children and pregnant women, as per WSJ. Yet, HHS award Moderna $590 million to develop mRNA vaccines against pandemic flu threats.
Moderna has also recently opened a manufacturing lab in the UK. Concerns have surfaced regarding the patentability of some of Moderna's mRNA patents, a major point in the ongoing vaccine wars. Despite some struggles, including missing Q1 revenue expectations and a decreased revenue, Moderna continues to advance, revealing a healthy immune response in older adults from a combo flu and COVID-19 shot. Moderna has already begun a Phase 1 Study on a novel cancer therapy candidate. Notably, Moderna, has been included in Billionaire David E. Shaw's small-cap stock picks with significant upside potential. Finally, Moderna has faced challenges with RFK Jr. as HHS secretary and is dealing with a 'hostile' FDA environment as it seeks cost cuts amid vaccine market uncertainty.
Moderna MRNA News Analytics from Tue, 02 Jul 2024 07:00:00 GMT to Sat, 17 May 2025 18:54:31 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor -3
